Handbook of Experimental Pharmacology

Continuation of Handbuch der experimentellen Pharmakologie

Vol. 67/II

Editorial Board
G. V. R. Born, London · A. Farah, Rensselaer, New York
H. Herken, Berlin · A. D. Welch, Memphis, Tennessee

Advisory Board
S. Ebashi · E. G. Erdös · V. Ersparser · U. S. von Euler · W. S. Feldberg
G. B. Koelle · M. Rocha e Silva · J. R. Vane · P. G. Waser
Antibiotics

Containing the Beta-Lactam Structure

Part II

Contributors
P. Actor·M. C. Browning·N. H. Georgopapadakou·J. R. E. Hoover
K. C. Kwan·A. K. Miller·J. D. Rogers·R. B. Sykes·B. M. Tune
J. V. Uri

Editors
A. L. Demain and N. A. Solomon

Springer-Verlag Berlin Heidelberg New York Tokyo 1983
CHAPTER 12
Bacterial Enzymes Interacting with β-Lactam Antibiotics
N. H. GEORGOPAPADAKOU and R. B. SYKES. With 10 Figures

A. Introduction .................................................. 1
   I. Classification of β-Lactam Antibiotics ...................... 3
   II. Mode of Action of β-Lactam Antibiotics .................. 4
       1. Structure and Synthesis of Peptidoglycan ............... 4
       2. The Tipper and Strominger Hypothesis for Penicillin Action . 7
   III. Classification of Enzymes Interacting with β-Lactam Antibiotics . 9
       1. Enzymes Acting on Peptidoglycan ......................... 9
       2. Enzymes Degrading β-Lactam Antibiotics .................. 10

B. Bacterial Proteins Binding β-Lactam Antibiotics .......... 12
   I. General ................................................... 12
   II. Penicillin-Binding Proteins in Gram-Negative Bacteria .... 15
       1. Escherichia coli .............................................. 15
       2. Other Enterobacteria ........................................ 17
       3. Pseudomonads ............................................... 20
       4. Other Bacteria .............................................. 21
   III. Penicillin-Binding Proteins in Gram-Positive Bacteria ... 21
       1. Bacilli ..................................................... 21
       2. Micrococci .................................................. 23
       3. Streptococci ............................................... 24
       4. Actinomycetes .............................................. 24

C. Enzymes Inhibited by β-Lactam Antibiotics ................. 25
   I. DD-Carboxypeptidases .................................... 25
       1. DD-Carboxypeptidases in Gram-Negative Bacteria ......... 30
       2. DD-Carboxypeptidases in Gram-Positive Bacteria ...... 31
   II. Peptidoglycan Transpeptidase ............................ 35

D. β-Lactamases .................................................. 36
   I. General ..................................................... 36
   II. β-Lactamases in Gram-Positive Bacteria .................. 37
       1. Staphylococci ............................................... 39
       2. Bacilli ...................................................... 40
       3. Streptomycetes .............................................. 43
       4. Other Actinomycetes ....................................... 43
CHAPTER 13

In Vitro and In Vivo Laboratory Evaluation of β-Lactam Antibiotics

A. K. MILLER

A. Historical

I. Penicillins

II. Cephalosporins

III. Cephamycins (7-α-Methoxy Cephalosporins)

IV. β-Lactams of Novel Structure

B. β-Lactams Laboratory Evaluation Procedures

I. Introduction

II. In Vitro Test Procedures

1. Spectrum of Activity and Sensitivity Tests

2. Speed of Action Test

3. Susceptibility Disc Test

4. Interaction and Synergy Tests

5. Effect on Morphology

6. Procedures Using Anaerobes

7. Factors Influencing In Vitro Tests

8. Enzymes and Resistance to β-Lactam Antibiotics

9. Automation and Miniaturization

10. In Vitro Models to Simulate In Vivo Conditions

III. In Vivo Test Procedures

1. Mouse Protection Test

2. Specialized Test Procedures

3. Tests Using Anaerobes

IV. In Vitro–In Vivo Relationships

C. Representative β-Lactam Agents

References
CHAPTER 14
\textit{ß}-Lactam Antibiotics: Structure–Activity Relationships. J. R. E. HOOVER
With 8 Figures

A. Introduction: Scope .................................................. 119
   I. Structure ..................................................... 119
   II. Activity .................................................. 121

B. Clinically Useful Penicillins ........................................ 122
   I. Natural, Biosynthetic, and Related Penicillins ............... 125
   II. Penicillinase-Resistant Penicillins ........................... 127
   III. Broad-Spectrum Penicillins .................................. 131
      1. \(\alpha\)-Aminopenicillins ................................... 132
      2. \(\alpha\)-Carboxy and \(\alpha\)-Sulfopenicillins .................... 134
      3. Acylampicillins ............................................ 136
      4. 6-Acylamino Alternatives: Quaternary Heterocyclic
          Aminopenicillanic Acids and 6-Amidinopenicillanic Acids 139
      5. A 6\(\alpha\)-Methoxy Penicillin (Temocillin) .................. 142

C. Clinically Useful Cephalosporins .................................. 144
   I. Basic Structure–Activity Relationships ....................... 144
   II. \(ß\)-Lactamase-Sensitive Cephalosporins ..................... 149
      1. 7\(ß\)-Acylamino Group Modifications ....................... 149
      2. Metabolic Stability ......................................... 153
      3. 3-Substituent Modifications ............................... 154
   III. Cephalosporins with Special Pharmacokinetic Properties 160
      1. Cephalosporins with High and Prolonged Serum Levels 161
      2. Cephalosporins Absorbed Orally .......................... 164
   IV. \(ß\)-Lactamase-Resistant Cephalosporins ...................... 168
      1. Cephalosporins with Moderate \(ß\)-Lactamase Resistance 168
      2. Cephamycins .............................................. 172
      3. Cephalosporins with Significant \(ß\)-Lactamase Resistance 174
   V. Oxacephalosporins ............................................ 180

D. Nonclassic \(ß\)-Lactams ............................................. 185
   I. Penems and Carbapenems ..................................... 185
      1. Carbapenems: Thienamycins, Olivanic Acids, and Related
          Structures .................................................. 186
      2. Penems .................................................... 197
      3. Oxapenems .................................................. 202
   II. Monocyclic \(ß\)-Lactams ....................................... 203
      1. Nocardicins .................................................. 203
      2. Monobactams .................................................. 206
   III. \(ß\)-Lactamase Inhibitors ...................................... 212
      1. Penicillins and Cephalosporins as Inhibitors .......... 212
      2. Progressive \(ß\)-Lactamase Inhibitors .................... 214

E. Other Structure–Activity Relationships .......................... 226

References ............................................................ 226
## A. Introduction

## B. Penicillins

### I. Benzylpenicillin (Penicillin G)

### II. Phenoxyalkylynpenicillins

1. Phenoxyethylpenicillin (Penicillin V)
2. Pheneticillin
3. Propicillin
4. Phenbenicillin

### III. Clometocillin

### IV. Methicillin

### V. Ancillin

### VI. Nafcillin

### VII. Isoxazolylpenicillins

1. Oxacillin
2. Cloxacillin
3. Dicloxacillin
4. Flucloxacillin

### VIII. Ampicillin

1. Hetacillin
2. Pivampicillin
3. Bacampicillin
4. Talampicillin
5. Metampicillin
6. Methoxymethyl Ester of Hetacillin

### IX. Amoxicillin

### X. Azidocillin

### XI. Epicillin

### XII. Cyclacillin

### XIII. Carbenicillin

1. Carindacillin
2. Carfecillin

### XIV. Ticarcillin

### XV. Sulbenicillin

### XVI. Ureidopenicillins

1. Azlocillin
2. Mezlocillin
3. Piperacillin
4. Bayk 4999
5. BL-P1654

## C. Cephalosporins

### I. Cephalosporanic Acids

1. Cephalothin
2. Cephapirin
CHAPTER 16

Toxicology of β-Lactam Antibiotics. M. C. BROWNING and B. M. TUNE

A. Introduction ........................................ 371

B. Local Reactions to Parenteral Administration ... 371
CHAPTER 17

Therapeutic Application of β-Lactam Antibiotics. J. V. Uri and P. Actor

A. Introduction ................................................................. 399

B. Penicillins in the Therapy of Human Infections ...................... 400
   I. The Penams: The Biosynthetic or Natural Penicillins .............. 406
      1. Penicillin G (Benzylpenicillin) ................................. 406
      2. Penicillin V and the Acid-Stable Phenoxypenicillins .......... 409
   II. The Penicillinase-Resistant Penicillins ......................... 410
      1. Methicillin ....................................................... 410
      2. Nafcillin ....................................................... 412
      3. Isoxazolyl Penicillins ......................................... 413
   III. The Broad-Spectrum Aminopenicillins .......................... 414
      1. Ampicillin ..................................................... 415
      2. Esters of Ampicillin ........................................... 417
      3. Amoxicillin .................................................... 418
      4. Epicillin and Cyclacillin .................................... 419
   IV. The Antipseudomonal Penicillins ................................ 419
      1. Carbenicillin .................................................. 420
      2. Ticarcillin ..................................................... 422
   V. The Amidinopenicillanic Acids – Amdinocillin .................... 425
   VI. The Atypical β-Lactams ........................................... 426
      1. The Monocyclic β-Lactams ..................................... 426
      2. The Oxapenams ................................................ 428
      3. The Carbapenems .............................................. 428
      4. The Penems .................................................... 429

C. Cephalosporins in the Therapy of Human Infections ............... 429
   I. Cephalothin ......................................................... 433
   II. Cephaloridine ..................................................... 433
   III. Cefazolin .......................................................... 434
   IV. Cefamandole ....................................................... 435
   V. Cefoxitin ............................................................ 436
   VI. Cefmetazole ....................................................... 436
   VII. Cefuroxime ....................................................... 437
   VIII. Ceforanide ....................................................... 437
   IX. Cefonicid ........................................................... 438
   X. Third-Generation Cephalosporins ................................. 438
      1. Cefotaxime ...................................................... 439
      2. Ceftizoxime ..................................................... 441
      3. Moxalactam ...................................................... 441
      4. Cefoperazone .................................................. 442
      5. Ceftriaxone ..................................................... 443
      6. Cefmenoxime .................................................... 443
      7. Ceftazidime ..................................................... 443
      8. Cefotiam ........................................................ 444
      9. Cefsulodin ....................................................... 444
XI. The Oral Cephalosporins ........................................ 445
   1. Cephalexin ............................................... 445
   2. Cephradine ............................................. 446
   3. Cefatrizine ............................................. 446
   4. Cefaclor ................................................ 446
   5. Cefroxadine, Cefadroxil, and Cephaloglycin ............. 447

D. Antibacterial Chemoprophylaxis with the β-Lactam Antibiotics ... 447
   I. Prophylactic Uses in Medicine ............................ 448
   II. Prophylactic Uses in Surgery ............................ 451

E. Use of β-Lactam Antibiotics in Dental Medicine .............. 453
F. Use of β-Lactam Antibiotics in Veterinary Practice ........... 455

References ................................................... 458

Subject Index .................................................. 471